Literature DB >> 11084080

Surgery and transplantation for hepatocellular cancer.

W J Wall1, P J Marotta.   

Abstract

1. Curative treatment of hepatocellular carcinoma (HCC) depends on early diagnosis. 2. The cure rate for operable HCC occurring in the absence of cirrhosis is only 10% to 25%. 3. Features of HCC in patients with cirrhosis that are associated with a 5-year survival rate of 75% after liver transplantation include (1) solitary tumor less than 5 cm; (2) 3 or fewer tumors, each less than 3 cm; and (3) absence of vascular invasion. 4. Advanced cirrhosis limits the widespread application of partial hepatectomy to patients with HCC. 5. Neoadjuvant therapy has not yet been proven to improve patient outcome for early-stage HCC that is promptly treated by transplantation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11084080     DOI: 10.1053/jlts.2000.19010

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  14 in total

1.  Perioperative allogenic blood transfusion is a poor prognostic factor after hepatocellular carcinoma surgery: a multi-center analysis.

Authors:  Hiroshi Wada; Hidetoshi Eguchi; Hiroaki Nagano; Shoji Kubo; Takuya Nakai; Masaki Kaibori; Michihiro Hayashi; Shigekazu Takemura; Shogo Tanaka; Yasuyuki Nakata; Kosuke Matsui; Morihiko Ishizaki; Fumitoshi Hirokawa; Koji Komeda; Kazuhisa Uchiyama; Masanori Kon; Yuichiro Doki; Masaki Mori
Journal:  Surg Today       Date:  2017-06-08       Impact factor: 2.549

2.  Living related liver transplantation: medical and social aspects of a controversial therapy.

Authors:  C E Broelsch; G Testa; A Alexandrou; M Malagó
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

Review 3.  Treatment of hepatocellular carcinoma by means of radiopharmaceuticals.

Authors:  Bieke Lambert; Christophe Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-08       Impact factor: 9.236

4.  Association of Increased Programmed Death Ligand 1 Expression and Regulatory T Cells Infiltration with Higher Hepatocellular Carcinoma Recurrence in Patients with Hepatitis B Virus Pre-S2 Mutant after Curative Surgical Resection.

Authors:  Long-Bin Jeng; Tsai-Chung Li; Shih-Chao Hsu; Chiao-Fang Teng
Journal:  Viruses       Date:  2022-06-20       Impact factor: 5.818

5.  Decreasing disparity in liver transplantation among white and Asian patients with hepatocellular carcinoma : California, 1998-2005.

Authors:  Anthony S Robbins; Michael F Daily; Christopher A Aoki; Moon S Chen; Christoph Troppmann; Richard V Perez
Journal:  Cancer       Date:  2008-10-15       Impact factor: 6.860

6.  Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver.

Authors:  Marco Vivarelli; Alfredo Guglielmi; Andrea Ruzzenente; Alessandro Cucchetti; Roberto Bellusci; Claudio Cordiano; Antonino Cavallari
Journal:  Ann Surg       Date:  2004-07       Impact factor: 12.969

Review 7.  Liver embolizations in oncology: a review. Part I. Arterial (chemo)embolizations.

Authors:  Peter Gunvén
Journal:  Med Oncol       Date:  2007-08-03       Impact factor: 3.064

8.  Perioperative allogenenic blood transfusion is associated with worse clinical outcomes for hepatocellular carcinoma: a meta-analysis.

Authors:  Lei Liu; Zhiwei Wang; Songqi Jiang; Bingfeng Shao; Jibing Liu; Suqing Zhang; Yilong Zhou; Yuan Zhou; Yixin Zhang
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

9.  Combination therapy with dendritic cell vaccine and programmed death ligand 1 immune checkpoint inhibitor for hepatocellular carcinoma in an orthotopic mouse model.

Authors:  Chiao-Fang Teng; Ting Wang; Tzu-Hua Wu; Jia-Hui Lin; Fu-Ying Shih; Woei-Cherng Shyu; Long-Bin Jeng
Journal:  Ther Adv Med Oncol       Date:  2020-06-10       Impact factor: 8.168

10.  A Next-Generation Sequencing-Based Platform for Quantitative Detection of Hepatitis B Virus Pre-S Mutants in Plasma of Hepatocellular Carcinoma Patients.

Authors:  Chiao-Fang Teng; Hsi-Yuan Huang; Tsai-Chung Li; Woei-Cherng Shyu; Han-Chieh Wu; Chien-Yu Lin; Ih-Jen Su; Long-Bin Jeng
Journal:  Sci Rep       Date:  2018-10-04       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.